We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sampling Device Increases Detection of Barrett’s Esophagus

By LabMedica International staff writers
Posted on 12 Apr 2018
Esophageal adenocarcinoma, one of the most fatal and fastest growing cancers in the USA, can be prevented if detected at a precancerous stage. More...
In Barrett’s esophagus (BE), esophageal squamous mucosa is replaced by metaplastic columnar mucosa predisposed to developing esophageal adenocarcinoma (EAC).

Gastroenterologists perform more than five million upper endoscopies each year on patients with chronic heartburn and Barrett's esophagus in an effort to find these precancerous cells before they can progress to cancer. Despite the inability to accurately predict which patients have BE prior to endoscopy, BE is known to develop more frequently in men than women.

Scientists working with the University of Rochester Medical Center (Rochester, NY, USA) conducted a multicenter prospective trial, and enrolled 4,203 patients screened for suspected BE and those with known BE undergoing surveillance in 25 community-based gastrointestinal (GI) centers across the USA. Barrett’s esophagus (BE) and esophageal dysplasia (ED) are frequently missed during screening and surveillance esophagoscopy because of sampling error associated with four-quadrant random forceps biopsy (FB).

The scientists used Wide Area Transepithelial Sampling with 3D Tissue Analysis and were able to rapidly collect a sample from a much larger surface area of the esophagus. By combining a larger sampling area with patented 3D imaging and expert cytopathology, WATS3D has far reaching implications for protecting a patient’s health. If precancerous cells are present, they can now be easily detected and removed or destroyed before they become cancerous, essentially preempting esophageal cancer.

The authors reports that of 4,203 patients, 594 were diagnosed with BE by FB alone, and 493 additional cases were detected by adding WATS, increasing the overall detection of BE by 83% (493/594, 95% CI 74%–93%). Low-grade dysplasia (LGD) was diagnosed in 26 patients by FB alone, and 23 additional cases were detected by adding WATS, increasing the detection of LGD by 88.5% (23/26, 95% CI 48%–160%). The study was conducted predominantly on gastroesophageal reflux disease (GERD) patients who did not have a history of BE, the average BE length diagnosed in the study was less than 1.5 cm, which may result in lower endoscopic diagnostic accuracy.

Seth Gross, MD, a gastroenterologist and lead author of the study said, “These data confirm findings from previous clinical trials showing that WATS3D biopsy significantly increases the detection rate of Barrett's Esophagus as well as precancerous changes in esophageal tissue in GERD patients. Ultimately, WATS3D revolutionary technology is making esophageal cancer a potentially preventable disease.” The study was originally published on November 28, 2017, in the journal United European Gastroenterology Journal. The WATS3D study was also highlighted as part of the ASGE’s Scope Tech Talk video series and distributed to over 15,000 members in January 2018.

Related Links:
University of Rochester Medical Center


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.